Belgian drugmaker UCB says that Cimzia (certolizumab pegol CDP870), its anti-tumor necrosis factor-based therapeutic, has demonstrated efficacy in the treatment of patients with moderate to severe psoriasis. The firm added that the drug brought about a statistically-significant increase in the number of patients achieving a 75% improvement in their Psoriasis Area Severity Index score.
Pegylated therapeutic antibody
Cimzia is a humanized anti-TNF alpha antibody, which selectively targets human TNF-alpha, thereby neutralizing its pathophysiological effects. The firm said that the addition of a polyethylene glycol moiety to the compound marks it out as distinct from other currently-available anti-TNF therapies, which generally do not have this modification and therefore have shorter functional half-lives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze